Pharmacological characterization and antidiabetic activity of a long‐acting glucagon‐like peptide‐1 analogue conjugated to an antithrombin III‐binding pentasaccharide

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 8, 2015-08 ,pp. : 760-770

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ameliorating effect of the novel dipeptidyl peptidase‐4 inhibitor teneligliptin on psoriasis: A report of two cases

By  

THE JOURNAL OF DERMATOLOGY, Vol. 42, Iss. 11, 2015-11 ,pp. : 1094-1097

John Wiley & Sons Inc

Access to resources Recommend Favorite

Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression

By  

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 21, 2015-11 ,pp. : 5096-5109

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes

By Herman Gary A.   Bergman Arthur   Yi Bingming   Kipnes Mark    

Current Medical Research and Opinion, Vol. 22, Iss. 10, 2006-10 ,pp. : 1939-1947

Informa Healthcare

Access to resources Recommend Favorite

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite